ResMed (NYSE:RMD) and Google (NSDQ:GOOG) life sciences company Verily said today they inked a new joint venture deal aiming to develop software solutions to improve diagnosis, treatment and care for sleep apnea and other breathing related sleep disorders.
The new US-based joint venture will use sleep apnea knowledge from San Diego-based ResMed and Verily’s data analytics technologies in its pursuits, the companies said, and will operate as a separate venture from both ResMed and Verily.
“The vast majority of people with sleep apnea don’t realize they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks. The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life,” ResMed chief medical officer Dr. Carlos Nunez said in a prepared statement.
“Approaching a widespread health problem like sleep apnea through collecting, organizing and activating health data is central to Verily’s mission. By better identifying at-risk individuals as well as generating real-world evidence regarding the value and effectiveness of treatment, this collaboration has the potential to improve outcomes for millions of people living with sleep apnea, and potentially other related conditions,” Verily chief medical & scientific officer Dr. Jessica Mega said in a press release.
In May, a report emerged claiming Verily is looking to develop a painless blood collection system using microneedles and magnets.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.